IMMUNE & THYMIC / COLOPHON
About This Digest
A citation-anchored survey of the thymulin and KPV research record. Nothing sold, no one treated, no advice given.
What this desk covers
municipalpeptides is a data-forward digest of the published research on two peptides studied for immune modulation: thymulin, a zinc-dependent thymic hormone, and KPV, a tripeptide fragment of alpha-MSH. Both are grouped here under one theme — immunomodulation research — because both suppress the same core inflammatory signaling pathway, NF-kB, from two very different starting points: one systemic and hormone-linked, one local and delivery-engineered.
Each peptide holds its own page, cited claim by claim, with the studies' species, models, and outcomes reported exactly as published. A comparison page lines the two up directly. A shared reference list gathers every source drawn on across the site, with a DOI or PubMed link wherever one exists.
How we read the evidence
This site foregrounds the numbers: effect sizes, sample sizes, study duration, and species — the study-design details that determine how far a finding actually reaches. A 20-day reversal of asthma pathology in mice is reported as exactly that: a 20-day finding in mice, not a forecast about a person [1]. Where the literature is thin — and for both peptides here, it largely is — the text says so plainly rather than smoothing the gap with confident language.
Both peptides sit closer to the preclinical end of the research spectrum than most compounds covered across this network of sites. Thymulin has some directly human data, from decades-old zinc-status studies [6]; KPV has none published. Every review or synthesis source is marked as such, distinct from primary trial data, and every DOI or PMID cited here was checked against the original record rather than copied from a secondary aggregator.
The edges of this site
municipalpeptides is not a pharmacy, clinic, or supplier. Nothing is sold, sourced, or brokered here — no peptide, no research chemical — and no chemical supplier or clinic pays for placement on this page. No clinician is on staff, nothing is diagnosed, and no dose, schedule, or route is ever named for a person; where a dose appears, it is the dose used in a cited study, not a recommendation.
Neither thymulin nor KPV is approved by the FDA or any regulator for any human indication. Both are handled and described here strictly as research peptides for laboratory use. Anyone seeking guidance about actual human use of any peptide should take that question to a licensed clinician in their own jurisdiction; this site cannot and does not answer it. Corrections, citation fixes, or newly published studies can be sent through the contact page.